AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16516844 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical keyboard
Number of subjects: 9
Study 15031276 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention to promote eating five or more portions of fruit and vegetables a day
Number of subjects: 40
Study 15031276 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial intervention appointment discussions
Number of subjects: 40
Study 15031276 — intervention group
Group type: EXPERIMENTAL
Intervention: Final appointment discussions after 6 months
Number of subjects: 40
Study 11348956 — intervention group
Group type: EXPERIMENTAL
Intervention: IV diltiazem (n = 167)
Number of subjects: 330
Study 11348956 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 163)
Number of subjects: 330
Study 11348956 — intervention group
Group type: EXPERIMENTAL
Intervention: IV diltiazem
Number of subjects: 330
Study 11348956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 10436538 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid dipstick tests for nitrite and leucocyte esterase
Number of subjects: 375
Study 10436538 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid dipstick tests for nitrite and leucocyte esterase in children less than one year old
Number of subjects: 375
Study 10436538 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte esterase strip test
Number of subjects: 375
Study 10436538 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucocyte esterase strip test in children less than one year old
Number of subjects: 375
Study 8061850 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirapril
Number of subjects: 0
Study 8061850 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiraprilat
Number of subjects: 0
Study 2468896 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg p.o.
Number of subjects: 7
Study 2468896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31567997 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 86
Study 31567997 — intervention group
Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 86
Study 28987445 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of IIV4 and PPV23
Number of subjects: 334
Study 28987445 — intervention group
Group type: COMPARATOR
Intervention: Separate administration of IIV4 and PPV23
Number of subjects: 334
Study 25224961 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal Access Spine Technologies (MAST) approach
Number of subjects: 61
Study 25224961 — intervention group
Group type: COMPARATOR
Intervention: Conventional Open Approach (COA)
Number of subjects: 61
Study 22677718 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg three times a day, increasing to maximum tolerated dose or 120 mg three times a day for 7 days)
Number of subjects: 30
Study 22677718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21292873 — intervention group
Group type: EXPERIMENTAL
Intervention: Montanide ISA 720
Number of subjects: 40
Study 21292873 — intervention group
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51
Number of subjects: 40
Study 21292873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21292873 — intervention group
Group type: EXPERIMENTAL
Intervention: N, R, and C peptides
Number of subjects: 40
Study 17541211 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI temocapril (T) 2 mg/day
Number of subjects: 164
Study 17541211 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB candesartan (C) 4 mg/day
Number of subjects: 164
Study 17541211 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (T+C)
Number of subjects: 164
Study 17541211 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (C+T)
Number of subjects: 164
Study 17541211 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine-CR (N) 20 mg/day
Number of subjects: 164
Study 17541211 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI temocapril (T)
Number of subjects: 164
Study 17541211 — intervention group
Group type: EXPERIMENTAL
Intervention: ARB candesartan (C)
Number of subjects: 164
Study 17541211 — intervention group
Group type: EXPERIMENTAL
Intervention: ACEI and/or ARB
Number of subjects: 164
Study 17541211 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low doses of ACEI and ARB
Number of subjects: 164
Study 15704503 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive exercise programme and back school education
Number of subjects: 60
Study 15704503 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise programme and back school education
Number of subjects: 60
Study 15704503 — intervention group
Group type: COMPARATOR
Intervention: Control group (no education or exercise)
Number of subjects: 60
Study 11932280 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (E) alone
Number of subjects: 59
Study 11932280 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T) alone
Number of subjects: 59
Study 11932280 — intervention group
Group type: COMPARATOR
Intervention: Both E and T withdrawn
Number of subjects: 59
Study 9459322 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V Leiden positive subjects
Number of subjects: 165
Study 9459322 — intervention group
Group type: COMPARATOR
Intervention: Factor V Leiden negative subjects
Number of subjects: 165
Study 9459322 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor V Leiden positive and negative subjects
Number of subjects: 165
Study 7615407 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent mandatory ventilation (IMV) at 10 breaths per minute
Number of subjects: 7
Study 7615407 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent mandatory ventilation (IMV) at 20 breaths per minute
Number of subjects: 7
Study 7615407 — intervention group
Group type: COMPARATOR
Intervention: Intermittent mandatory ventilation (IMV) rates of 10 and 20 breaths per minute
Number of subjects: 7
Study 2550046 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (ISO) infusion
Number of subjects: 0
Study 2550046 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoprenaline (ISO) bolus injections
Number of subjects: 0
Study 779587 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.225 mg daily (mean dosage varied from 0.225 to 0.900 mg)
Number of subjects: 42
Study 779587 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol 200 mg daily (mean dosage varied from 200 to 600 mg)
Number of subjects: 42
Study 779587 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorothiazide 25 mg added to clonidine in 15 cases
Number of subjects: 42
Study 779587 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorothiazide 25 mg added to practolol in 18 cases
Number of subjects: 42
Study 30088285 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents as Teachers (PAT) program
Number of subjects: 251
Study 26599038 — intervention group
Group type: EXPERIMENTAL
Intervention: LcS‐fermented milk
Number of subjects: 72
Study 26599038 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 72
Study 25517820 — intervention group
Group type: EXPERIMENTAL
Intervention: RMP formulation E
Number of subjects: 0
Study 25517820 — intervention group
Group type: EXPERIMENTAL
Intervention: INH formulations A, B, C, and D
Number of subjects: 0
Study 25517820 — intervention group
Group type: COMPARATOR
Intervention: RMP formulations A, B, C, and D
Number of subjects: 0
Study 25517820 — intervention group
Group type: COMPARATOR
Intervention: INH formulation E
Number of subjects: 0
Study 22821273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac troponin (cTn)
Number of subjects: 2121
Study 22821273 — intervention group
Group type: COMPARATOR
Intervention: CK-MB mass
Number of subjects: 2121
Study 22821273 — intervention group
Group type: COMPARATOR
Intervention: CK-based definition of MI
Number of subjects: 2121
Study 20230611 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication review and cognitive behaviour therapy by community pharmacists
Number of subjects: 342
Study 20230611 — intervention group
Group type: COMPARATOR
Intervention: Usual care according to the Dutch Pharmacy Standard
Number of subjects: 342
Study 20230611 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Treatment
Number of subjects: 342
Study 20230611 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Adherence Report Scale Questionnaire
Number of subjects: 342
Study 20230611 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 12 months
Number of subjects: 342
Study 17900325 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraflex stent
Number of subjects: 125
Study 17900325 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyflex stent
Number of subjects: 125
Study 17900325 — intervention group
Group type: EXPERIMENTAL
Intervention: Niti-S stent
Number of subjects: 125
Study 17900325 — intervention group
Group type: COMPARATOR
Intervention: All stents
Number of subjects: 125
Study 15799725 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 40
Study 15799725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12749486 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 780
Study 11092511 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-fat diet
Number of subjects: 0
Study 11092511 — intervention group
Group type: EXPERIMENTAL
Intervention: Background diet high in carbohydrate
Number of subjects: 0
Study 11092511 — intervention group
Group type: EXPERIMENTAL
Intervention: Background diet high in monounsaturated fatty acids (MUFAs)
Number of subjects: 0
Study 8819441 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervex brush
Number of subjects: 15882
Study 8819441 — intervention group
Group type: COMPARATOR
Intervention: Aylesbury spatula
Number of subjects: 15882
Study 1578912 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation (BMT)
Number of subjects: 223
Study 1578912 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Transplantation (ABMT)
Number of subjects: 223
Study 1578912 — intervention group
Group type: COMPARATOR
Intervention: Intensive Consolidation Chemotherapy (ICC)
Number of subjects: 223
Study 3935869 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (3 X 400 micrograms intranasally)
Number of subjects: 31
Study 3935869 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (2 X 1 mg subcutaneously after parenteral treatment with 3 mg per day in the first week)
Number of subjects: 31
Study 3935869 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (3 X 400 micrograms intranasally) + Tamoxifen (2 X 20 mg)
Number of subjects: 31
Study 3935869 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (3 X 400 micrograms intranasally) + Megestrol acetate (4 X 45 mg)
Number of subjects: 31
Study 3935869 — intervention group
Group type: COMPARATOR
Intervention: Buserelin alone
Number of subjects: 31
Study 31414562 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 295
Study 31414562 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 295
Study 31414562 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 295
Study 29560543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) at high frequency (400 bpm)
Number of subjects: 4
Study 29560543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) at medium frequency (200 bpm)
Number of subjects: 4
Study 29560543 — intervention group
Group type: COMPARATOR
Intervention: Autogenic drainage (AD)
Number of subjects: 4
Study 27080498 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² on day 1 and day 6 during the first two courses of chemotherapy) plus chemotherapy (lymphome malin B [LMB])
Number of subjects: 260
Study 27080498 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (no rituximab)
Number of subjects: 260
Study 24675955 — intervention group
Group type: EXPERIMENTAL
Intervention: Carolina Abecedarian Project (ABC)
Number of subjects: 100
Study 24675955 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 21696703 — intervention group
Group type: EXPERIMENTAL
Intervention: Discomfort evaluation system
Number of subjects: 72
Study 21696703 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuum evaluation system
Number of subjects: 72
Study 21696703 — intervention group
Group type: COMPARATOR
Intervention: Comfort evaluation system
Number of subjects: 72
Study 21199120 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Control Ventilation (PCV)
Number of subjects: 40
Study 21199120 — intervention group
Group type: COMPARATOR
Intervention: Volume Control Ventilation (VCV)
Number of subjects: 40
Study 17611322 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with midazolam (Group A and B: 16-25 mg/10s; Group C and D: 6-7 mg/10s)
Number of subjects: 400
Study 17611322 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with midazolam (Group A and B: 30 seconds to 1 minute interval; Group C and D: 3 to 5 minute interval)
Number of subjects: 400
Study 16086933 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA occlusion using sutures
Number of subjects: 77
Study 16086933 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA occlusion using a stapler
Number of subjects: 77
Study 16086933 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LAA occlusion)
Number of subjects: 77
Study 16086933 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative follow-up
Number of subjects: 77
Study 16086933 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon experience
Number of subjects: 77
Study 12383044 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux sodium 10mg subcutaneously for 7 days
Number of subjects: 24
Study 12383044 — intervention group
Group type: COMPARATOR
Intervention: Digoxin 0.25mg orally for 7 days
Number of subjects: 24
Study 12383044 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of fondaparinux sodium 10mg and digoxin 0.25mg
Number of subjects: 24
Study 10597550 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 7% followed by maintenance with 1.7%
Number of subjects: 120
Study 10597550 — intervention group
Group type: COMPARATOR
Intervention: Propofol 3 mg.kg‐1 followed by a maintenance infusion of 5 mg.kg‐1.h‐1
Number of subjects: 120
Study 8567345 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative concomitant radiochemotherapy (two courses of 18.5 Gy in five fractions, continuous infusion of 5-FU 800 mg/m2 days 1-5 and cisplatinum 70 mg/m2 day 2)
Number of subjects: 56
Study 8567345 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative concomitant radiochemotherapy
Number of subjects: 56
Study 1824249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine (Ara‐C) 100 mg/m2 (A100)
Number of subjects: 326
Study 1824249 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine (Ara‐C) 200 mg/m2 (A200)
Number of subjects: 326
Study 6419632 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal analgesia with sedation
Number of subjects: 60
Study 6419632 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with controlled ventilation
Number of subjects: 60
Study 31558596 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated interactive voice messages promoting contraceptive use (at least 11 messages over 4 months)
Number of subjects: 969
Study 31558596 — intervention group
Group type: COMPARATOR
Intervention: Control group (no messages)
Number of subjects: 969
Study 31558596 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated interactive voice messages promoting contraceptive use
Number of subjects: 969
Study 29525617 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide administered 1 hour preoperatively
Number of subjects: 96
Study 29525617 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acetazolamide administered 3 hours postoperatively
Number of subjects: 96
Study 29525617 — intervention group
Group type: COMPARATOR
Intervention: No administration of acetazolamide
Number of subjects: 96
Study 26340097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solifenacin succinate 5 mg/day
Number of subjects: 80
Study 26340097 — intervention group
Group type: COMPARATOR
Intervention: Healthy female subjects (control group)
Number of subjects: 80
Study 24196467 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical (intra-articular) tranexamic acid
Number of subjects: 161
Study 21256649 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (3 mg)
Number of subjects: 20
Study 21256649 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 20
Study 19194326 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI, 5-10 minutes) + Internet program
Number of subjects: 84
Study 19194326 — intervention group
Group type: COMPARATOR
Intervention: Brief Advice (BA, 1-2 minutes) + Internet program
Number of subjects: 84
Study 16481638 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose adjuvant interferon alfa-2b
Number of subjects: 200
Study 15215813 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 80 mg
Number of subjects: 383
Study 15215813 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg
Number of subjects: 383
Study 15215813 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 383
Study 15215813 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 5 mg and 10 mg
Number of subjects: 383
Study 15215813 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (all doses)
Number of subjects: 383
Study 15215813 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 383
Study 15215813 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 383
Study 10974371 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination antiretroviral treatment
Number of subjects: 45
Study 9314129 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary sclerosing cholangitis
Number of subjects: 134
Study 9314129 — intervention group
Group type: COMPARATOR
Intervention: No primary sclerosing cholangitis
Number of subjects: 134
Study 8136092 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril treatment
Number of subjects: 10
Study 8136092 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 10
Study 3720279 — intervention group
Group type: EXPERIMENTAL
Intervention: Token financial incentive of two cents for returning the questionnaire
Number of subjects: 0
Study 3720279 — intervention group
Group type: COMPARATOR
Intervention: No token financial incentive
Number of subjects: 0
Study 31184579 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg
Number of subjects: 0
Study 31184579 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg
Number of subjects: 0
Study 31184579 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg
Number of subjects: 0
Study 29149618 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred, empowerment-based self-management programme (6 weeks)
Number of subjects: 242
Study 29149618 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred, empowerment-based self-management programme
Number of subjects: 242
Study 29149618 — intervention group
Group type: COMPARATOR
Intervention: Attentional control (health education classes and post-discharge follow-up)
Number of subjects: 242
Study 27997673 — intervention group
Group type: EXPERIMENTAL
Intervention: Genium knee
Number of subjects: 25
Study 27997673 — intervention group
Group type: COMPARATOR
Intervention: C-Leg
Number of subjects: 25
Study 25518030 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative oxygen supplementation via nasal catheter
Number of subjects: 109
Study 25518030 — intervention group
Group type: COMPARATOR
Intervention: No postoperative oxygen supplementation
Number of subjects: 109
Study 22595363 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (8 mg/day for 4 weeks, then 16 mg/day for 12 weeks)
Number of subjects: 45
Study 22595363 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 20526694 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric group (B)
Number of subjects: 20
Study 20526694 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 20
Study 18955453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked diet (no raw fruits or vegetables)
Number of subjects: 153
Study 18955453 — intervention group
Group type: COMPARATOR
Intervention: Raw diet (fresh fruit and fresh vegetables)
Number of subjects: 153
Study 18955453 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked diet
Number of subjects: 153
Study 18955453 — intervention group
Group type: COMPARATOR
Intervention: Raw diet
Number of subjects: 153
Study 18955453 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 153
Study 19368781 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa vaccine
Number of subjects: 100
Study 19368781 — intervention group
Group type: EXPERIMENTAL
Intervention: dTpa vaccine
Number of subjects: 100
Study 19368781 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis A control vaccine
Number of subjects: 100
Study 15688965 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Stimulation Distraction Device (MSDD)
Number of subjects: 100
Study 15688965 — intervention group
Group type: COMPARATOR
Intervention: No Manual Stimulation Distraction Device (Control)
Number of subjects: 100
Study 12413615 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of mifepristone alone (Group 1)
Number of subjects: 400
Study 12413615 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of tamoxifen with 10 mg of mifepristone (Group 2)
Number of subjects: 400
Study 9042043 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide via Turbuhaler (0.4, 0.8, 1.6, and 2.4 mg/day for 2 weeks)
Number of subjects: 58
Study 7930659 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of aspirin per day
Number of subjects: 46
Study 7930659 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin)
Number of subjects: 46
Study 3251510 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 6